CN105092757A - 一种克林霉素磷酸酯的分析方法 - Google Patents
一种克林霉素磷酸酯的分析方法 Download PDFInfo
- Publication number
- CN105092757A CN105092757A CN201510473448.XA CN201510473448A CN105092757A CN 105092757 A CN105092757 A CN 105092757A CN 201510473448 A CN201510473448 A CN 201510473448A CN 105092757 A CN105092757 A CN 105092757A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- clindamycin phosphate
- oxidation impurities
- phosphate
- acetonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
本发明涉及一种克林霉素磷酸酯氧化杂质,其通过对克林霉素磷酸酯在双氧水中氧化得到。该分析方法操作简单,适合该杂质的快速检测。
Description
技术领域
本发明涉及药物分析化学领域,特别涉及克林霉素磷酸酯氧化杂质的分析和制备方法。
背景技术
克林霉素磷酸酯属于克林霉素前药,其在体内可迅速水解为克林霉素而显示药理活性。相比于克林霉素,克林霉素磷酸酯具有抗菌活性高、吸收快、脂溶性及渗透性强、副作用少等特点。
克林霉素磷酸酯分子结构中含有磷酸酯键、硫甲基、卤素等活泼基团,易发生水解、氧化、取代、消除、重排等反应。分子中含有硫原子,易被氧化产生高价硫,或在酸性条件下磷酸酯键和硫甲基易水解。在碱性或受热时化合物容易产生卤素水解和消除反应。在上述降解过程中还会发生异构化反应。
由于克林霉素磷酸酯的稳定性低,因此对其稳定性和有关物质的充分研究对于保障药品安全至关重要。
发明内容
我们对克林霉素磷酸酯在酸破坏、碱破坏、热破坏、氧破坏以及光破坏下的的稳定性进行了研究。
母液的制备:精密称取克林霉素磷酸酯1882.48mg,置25ml量瓶中,加流动相A溶解并稀释至刻度,摇匀,室温放置,作为破坏性试验的母液。
a.酸破坏:精密吸取母液1ml,置25ml量瓶中,加入1ml1mol/L盐酸溶液,充分摇匀,室温下放置10h,用1ml1mol/L氢氧化钠溶液中和后,加流动相稀释至刻度,摇匀。
b.碱破坏:精密吸取母液1ml,置25ml量瓶中,加入1ml1mol/L氢氧化钠溶液,充分摇匀,室温下放置10h,用1ml1mol/L盐酸溶液中和后,加流动相稀释至刻度,摇匀。
c.热破坏:精密吸取母液1ml,置25ml量瓶中,加流动相稀释至刻度,摇匀,置100℃水浴中加热30min,取出,放冷至室温。
d.氧破坏:精密吸取母液1ml,置25ml量瓶中,加入2ml2%双氧水溶液,充分摇匀,室温下放置30min,加流动相稀释至刻度,摇匀。
e.光破坏:精密吸取母液1ml,置25ml量瓶中,5000lx照度下放置10小时,加流动相稀释至刻度,摇匀。
精密量取上述溶液各20μl注入液相色谱仪,并对各有关物质进行归属。
表1、破坏性试验样品的杂质与主成分含量(归一化法)及杂质归属
通过对比可以发现,样品在酸破坏、光照破坏条件下,杂质均没有明显变化;在碱破坏条件下,杂质G有所增加,有少量杂质A生成;在加热破坏条件下,有大量杂质F,杂质E生成,相对保留时间0.10,0.11,0.13,0.16,0.75处,均有少量杂质生成;在氧化破坏条件下,有大量杂质A生成,并且在相对保留时间0.33处有一个含量9.99%的未知杂质生成。
由于该氧化杂质含量较大,因此有必要对其进一步进行研究。
本发明涉及一种克拉霉素磷酸酯氧化杂质的分析方法:
(1)母液的制备:精密称取克林霉素磷酸酯1882.48mg,置25ml量瓶中,加流动相A溶解并稀释至刻度,摇匀,室温放置,作为破坏性试验的母液;
(2)氧化:精密吸取母液1ml,置25ml量瓶中,加入2ml2%双氧水溶液,充分摇匀,室温下放置30min,加流动相稀释至刻度,摇匀;
(3)分离:精密量取上述溶液20μl注入高效液相色谱仪,利用二维液相进行分析和检测:
A、一维液相色谱条件:
流动相A:0.1mol/L磷酸二氢钾溶液:乙腈=790:210,v/v
流动相B:0.1mol/L磷酸二氢钾溶液:乙腈=400:600,v/v
柱温30℃;
流速为每分钟1.1ml;
检测波长为210nm;
梯度洗脱条件:
时间(min) | 流动相A | 流动相B |
0 | 100 | 0 |
13 | 100 | 0 |
18 | 50 | 50 |
39 | 50 | 50 |
40 | 100 | 0 |
50 | 100 | 0 |
B、二维液相色谱条件:
流动相A:0.1%甲酸
流动相B:乙腈
时间(min) | 流动相A | 流动相B |
0 | 95 | 5 |
1 | 95 | 5 |
10 | 0 | 100 |
C、质谱:安捷伦Q-TOF电压:+175V
截取一维液相中较大的未知杂质,进入二维液相,起始1分钟冲去磷酸盐,再将样品冲入高分辨质谱仪,确定该氧化杂质的精确质量为521.1200,其元素组成为C18H35N2O9PSCl,结构为:。
所述0.1mol/L磷酸二氢钾溶液采用450mg/mL的氢氧化钾溶液调pH值至6.0得到。
本发明的分析方法操作简便,非常适合克林霉素磷酸酯氧化杂质的快速检测。
附图说明
图1为克林霉素磷酸酯氧破坏后的LC-MS图谱。
具体实施方式
精密称取克林霉素磷酸酯1882.48mg,置25ml量瓶中,加流动相A溶解并稀释至刻度,摇匀,室温放置,作为破坏性试验的母液;
精密吸取母液1ml,置25ml量瓶中,加入2ml2%双氧水溶液,充分摇匀,室温下放置30min,加流动相稀释至刻度,摇匀;
精密量取上述溶液20μl注入高效液相色谱仪,利用二维液相进行分析和检测。
A、一维液相色谱条件:
流动相A:0.1mol/L磷酸二氢钾溶液(采用450mg/mL的氢氧化钾溶液调pH值至6.0得到):乙腈=790:210,v/v
流动相B:0.1mol/L磷酸二氢钾溶液(采用450mg/mL的氢氧化钾溶液调pH值至6.0得到):乙腈=400:600,v/v
柱温30℃;流速为每分钟1.1ml;检测波长为210nm;
梯度洗脱条件:
时间(min) | 流动相A | 流动相B |
0 | 100 | 0 |
13 | 100 | 0 |
18 | 50 | 50 |
39 | 50 | 50 |
40 | 100 | 0 |
50 | 100 | 0 |
B、二维液相色谱条件:
流动相A:0.1%甲酸
流动相B:乙腈
时间(min) | 流动相A | 流动相B |
0 | 95 | 5 |
1 | 95 | 5 |
10 | 0 | 100 |
质谱:安捷伦Q-TOF电压:+175V
截取一维液相中较大的未知杂质,进入二维液相,起始1分钟冲去磷酸盐,再将样品冲入高分辨质谱仪,确定该氧化杂质的精确质量为521.1200,其元素组成为C18H35N2O9PSCl,结构为:。
Claims (6)
1.一种克林霉素磷酸酯氧化杂质,其结构为:
。
2.一种克林霉素磷酸酯氧化杂质的分析方法,其包括如下步骤:
(1)母液的制备:精密称取克林霉素磷酸酯1882.48mg,置25ml量瓶中,加流动相溶解并稀释至刻度,摇匀,室温放置,作为母液;
(2)氧化:精密吸取母液1ml,置25ml量瓶中,加入2ml2%双氧水溶液,充分摇匀,室温下放置30min,加流动相稀释至刻度,摇匀;
(3)分离:精密量取上述溶液20μl注入高效液相色谱仪,利用二维液相进行分析和检测,高分辨质谱确定该氧化杂质的精确质量为521.1200,其元素组成为C18H35N2O9PSCl,结构为:。
3.根据权利要求2所述的克林霉素磷酸酯氧化杂质的分析方法,其特征在于:
A、一维液相色谱条件:
流动相A:0.1mol/L磷酸二氢钾溶液:乙腈=790:210,v/v;
流动相B:0.1mol/L磷酸二氢钾溶液:乙腈=400:600,v/v;
柱温30℃;
流速为每分钟1.1ml;
检测波长为210nm;
梯度洗脱条件:
B、二维液相色谱条件:
流动相A:0.1%甲酸;
流动相B:乙腈;
C:高分辨质谱:安捷伦Q-TOF,电压为+175V;
截取一维液相中较大的未知杂质,进入二维液相,起始1分钟冲去磷酸盐,再将样品冲入高分辨质谱仪。
4.根据权利要求2所述的克林霉素磷酸酯氧化杂质的分析方法,其特征在于:所述流动相为0.1mol/L磷酸二氢钾溶液:乙腈=790:210,v/v。
5.根据权利要求3或4所述的克林霉素磷酸酯氧化杂质的分析方法,其特征在于:所述0.1mol/L磷酸二氢钾溶液采用450mg/mL的氢氧化钾溶液调pH值至6.0得到。
6.根据权利要求3所述的克林霉素磷酸酯氧化杂质的分析方法,其特征在于:所述的较大的未知杂质的相对保留时间为0.33。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510473448.XA CN105092757B (zh) | 2015-08-06 | 2015-08-06 | 一种克林霉素磷酸酯的分析方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510473448.XA CN105092757B (zh) | 2015-08-06 | 2015-08-06 | 一种克林霉素磷酸酯的分析方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105092757A true CN105092757A (zh) | 2015-11-25 |
CN105092757B CN105092757B (zh) | 2016-09-07 |
Family
ID=54573664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510473448.XA Active CN105092757B (zh) | 2015-08-06 | 2015-08-06 | 一种克林霉素磷酸酯的分析方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105092757B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106950290A (zh) * | 2016-12-20 | 2017-07-14 | 宁夏多维药业有限公司 | 克林霉素磷酸酯凝胶中有关物质的检测方法 |
CN112684056A (zh) * | 2020-12-30 | 2021-04-20 | 海南海神同洲制药有限公司 | 一种克林霉素磷酸酯阴道片的含量测定方法 |
CN114354810A (zh) * | 2022-01-04 | 2022-04-15 | 武汉九州钰民医药科技有限公司 | 克林霉素磷酸酯中杂质n的检测方法、及杂质的分离方法 |
-
2015
- 2015-08-06 CN CN201510473448.XA patent/CN105092757B/zh active Active
Non-Patent Citations (8)
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106950290A (zh) * | 2016-12-20 | 2017-07-14 | 宁夏多维药业有限公司 | 克林霉素磷酸酯凝胶中有关物质的检测方法 |
CN106950290B (zh) * | 2016-12-20 | 2019-07-02 | 宁夏多维药业有限公司 | 克林霉素磷酸酯凝胶中有关物质的检测方法 |
CN112684056A (zh) * | 2020-12-30 | 2021-04-20 | 海南海神同洲制药有限公司 | 一种克林霉素磷酸酯阴道片的含量测定方法 |
CN112684056B (zh) * | 2020-12-30 | 2022-04-29 | 海南海神同洲制药有限公司 | 一种克林霉素磷酸酯阴道片的含量测定方法 |
WO2022142152A1 (zh) * | 2020-12-30 | 2022-07-07 | 海南海神同洲制药有限公司 | 一种克林霉素磷酸酯阴道片的含量测定方法 |
CN114354810A (zh) * | 2022-01-04 | 2022-04-15 | 武汉九州钰民医药科技有限公司 | 克林霉素磷酸酯中杂质n的检测方法、及杂质的分离方法 |
CN114354810B (zh) * | 2022-01-04 | 2024-04-19 | 武汉九州钰民医药科技有限公司 | 克林霉素磷酸酯中杂质n的检测方法、及杂质的分离方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105092757B (zh) | 2016-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Simultaneous quantification of 17 constituents from Yuanhu Zhitong tablet using rapid resolution liquid chromatography coupled with a triple quadrupole electrospray tandem mass spectrometry | |
Wang et al. | Simultaneous determination of five phenolic components and paeoniflorin in rat plasma by liquid chromatography–tandem mass spectrometry and pharmacokinetic study after oral administration of Cerebralcare granule® | |
Dong et al. | Ultrasound‐assisted aqueous two‐phase extraction of phenylethanoid glycosides from Cistanche deserticola YC Ma stems | |
Chen et al. | Modified Jiu Wei Qiang Huo decoction improves dysfunctional metabolomics in influenza A pneumonia‐infected mice | |
Sun et al. | UPLC–MS/MS performing pharmacokinetic and biodistribution studies of rhein | |
CN105092757A (zh) | 一种克林霉素磷酸酯的分析方法 | |
Wang et al. | Liquid chromatography tandem mass spectrometry in study of the pharmacokinetics of six steroidal saponins in rats | |
Xu et al. | Analysis of saikosaponins in rat plasma by anionic adducts‐based liquid chromatography tandem mass spectrometry method | |
Sun et al. | Simultaneous determination of four flavonoids and one phenolic acid in rat plasma by LC–MS/MS and its application to a pharmacokinetic study after oral administration of the Herba Desmodii Styracifolii extract | |
Zhao et al. | Simultaneous determination of nine coumarins in rat plasma by HPLC–MS/MS for pharmacokinetics studies following oral administration of Fraxini Cortex extract | |
CN105334301B (zh) | 一种吡咯并喹啉醌pqq二钠盐杂质的分离纯化方法 | |
Ma et al. | Simultaneous determination of Eleutheroside B and Eleutheroside E in rat plasma by high performance liquid chromatography–electrospray ionization mass spectrometry and its application in a pharmacokinetic study | |
Cao et al. | Plasma and brain pharmacokinetics of ganoderic acid A in rats determined by a developed UFLC–MS/MS method | |
Zhou et al. | Simultaneous determination of three flavonoids and one coumarin by LC–MS/MS: Application to a comparative pharmacokinetic study in normal and arthritic rats after oral administration of Daphne genkwa extract | |
Zhao et al. | Simultaneous determination of imperatorin and its metabolites in vitro and in vivo by a GC‐MS method: application to a bioavailability and protein binding ability study in rat plasma | |
Xu et al. | A rapid and sensitive determination of aucubin in rat plasma by liquid chromatography–tandem mass spectrometry and its pharmacokinetic application | |
Zhu et al. | Metabolic study of paeoniflorin and total paeony glucosides from Paeoniae Radix Rubra in rats by high‐performance liquid chromatography coupled with sequential mass spectrometry | |
Wang et al. | Comparative pharmacokinetic study of the main components of cortex fraxini after oral administration in normal and hyperuricemic rats | |
Qi et al. | Determination of chikusetsusaponin V and chikusetsusaponin IV in rat plasma by liquid chromatography–mass spectrometry and its application to a preliminary pharmacokinetic study | |
Zou et al. | Development of an LC/MS/MS method in order to determine arctigenin in rat plasma: its application to a pharmacokinetic study | |
Qi et al. | Simultaneous determination of cordycepin and its metabolite 3′‐deoxyinosine in rat whole blood by ultra‐high‐performance liquid chromatography coupled with Q Exactive hybrid quadrupole orbitrap high‐resolution accurate mass spectrometry and its application to accurate pharmacokinetic studies | |
Li et al. | Simultaneous determination of ginkgolides A, B, C and bilobalide by LC‐MS/MS and its application to a pharmacokinetic study in rats | |
Dai et al. | Simultaneous determination of notoginsenoside R1 and ginsenoside Re in rat plasma by ultra high performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study | |
Jiang et al. | Simultaneous determination of 14-thienyl methylene matrine and matrine in rat plasma by high-performance liquid chromatography–tandem mass spectrometry and its application in a pharmacokinetic study | |
Zhou et al. | Validated LC‐MS/MS method for the simultaneous determination of hyperoside and 2′′–O‐galloylhyperin in rat plasma: application to a pharmacokinetic study in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |